Developer docs
API playgroundTry for free, no card

Search company profiles

SAGA Diagnostics

Full company profile

uuid0000sdc

Namestring
SAGA Diagnostics
Legal namestring
SAGA Diagnostics US, Inc.
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMorrisville, United States
HQ citystring
Morrisville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular residual disease testing, liquid biopsy diagnostics, ctDNA cancer detection, structural variant analysis, cancer recurrence monitoring
Industry4 codes
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Molecular Diagnostics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Clinical Laboratory Diagnostic Testing
TypeSubscription Recurring
Description

SAGA operates a CLIA-certified laboratory offering the Pathlight MRD test to healthcare providers and patients in the U.S. Revenue is generated through Medicare reimbursement (for early-stage breast cancer) and commercial payor billing.

sagadiagnostics.com
2Biopharma Testing Services
TypeProfessional Services
Description

SAGA provides contract testing services to biopharma companies using Pathlight for clinical studies, biomarker discovery, trial enrollment support, and drug development programs. Services are tailored to each biopharma partner across early through late-stage cancer development programs.

sagadiagnostics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Medicare Reimbursement - Early-stage Breast Cancer
ModelOtherBilling cadencePay-as-you-go
Notes

Palmetto GBA's MolDX issued positive coverage decision for Medicare beneficiaries for recurrence monitoring in the surveillance setting for up to six years in patients with stage II-III breast cancer, including all subtypes: HR+/HER2-, HER2+ and TNBC.

sagadiagnostics.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Pathlight
Description

Ultra-sensitive, blood-based, multi-cancer molecular residual disease (MRD) test platform that uses whole genome sequencing and digital PCR to detect structural variants for cancer recurrence monitoring.

sagadiagnostics.com
Core offering1 text field

SAGA Diagnostics develops and commercializes Pathlight, an ultra-sensitive, blood-based molecular residual disease (MRD) test that combines whole genome sequencing with proprietary multiplex digital PCR to detect and track structural variants in circulating tumor DNA. The company operates a CLIA-certified laboratory in Morrisville, NC, providing diagnostic testing services to U.S. healthcare providers (initially for early-stage breast cancer recurrence monitoring) and biopharma companies for clinical trial support, biomarker discovery, and drug development programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100% sensitivity, 100% specificity, 13.7-month lead time to recurrence in stage I-III breast cancer
+3 more records
Product overview1 text field

SAGA Diagnostics offers a unified product portfolio centered on the Pathlight MRD platform. Pathlight is a first-of-its-kind, tumor-informed multi-cancer molecular residual disease (MRD) test that combines whole genome sequencing with proprietary multiplex digital PCR to detect and track structural variants as biomarkers for ultra-sensitive cancer recurrence monitoring. The platform serves both commercial clinical testing (initially for early-stage breast cancer with expansion to colorectal cancer) and biopharma partnership services for clinical trial support and drug development programs.

Product and service2 records
1Pathlight MRD Test
CategoryCancer Diagnostics
Description

Ultra-sensitive, blood-based, multi-cancer molecular residual disease (MRD) test that uses whole genome sequencing to identify tumor-specific structural variants and digital PCR to detect circulating tumor DNA at sub-part-per-million levels. Indicated for cancer recurrence monitoring and treatment response assessment, initially in early-stage breast cancer and expanded to colorectal cancer. Sold to oncologists, cancer centers, and academic medical centers.

2Biopharma Testing Services
CategoryClinical Trial Services
Description

Contract ctDNA-based liquid biopsy testing services for biopharma clinical development and translational research, including biomarker discovery, trial enrollment support, and longitudinal clinical trial monitoring using the Pathlight platform across solid tumors and hematologic malignancies. Sold to pharmaceutical and biotechnology companies of all sizes.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-16
Description

Roche entered into definitive merger agreement to acquire SAGA Diagnostics for up to $595 million. Following closing (expected Q3 2026), Foundation Medicine will integrate SAGA's Pathlight platform into its diagnostic portfolio. Plans to leverage Roche's AXELIOS sequencing and Digital LightCycler PCR platforms for decentralized MRD solutions.

2Top 10 Pharmaceutical Companies (unnamed)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pathlight is being used in clinical studies by multiple top 10 pharmaceutical companies for drug development, biomarker discovery, and clinical trial support. SAGA partners with biopharma companies of all sizes and development stages.

sagadiagnostics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Natera's Signatera is the leading tumor-informed MRD test using a personalized, multiplexed PCR (SNV-based) approach; it is the most directly comparable competitor in commercial-scale MRD testing for solid tumors.

TypeDirect peer
Description

Guardant Health's Guardant Reveal is a tumor-informed MRD product using a hybrid methylation/ctDNA approach. Guardant is a direct peer in liquid biopsy and MRD, with deeper commercial payor coverage in oncology.

TypeDirect peer
Description

Personalis offers NeXT Personal, a tumor-informed MRD test for solid tumors. It competes head-to-head with Pathlight in personalized ctDNA MRD detection, particularly in lung and breast cancer indications.

TypeDirect peer
Description

NeoGenomics sells RaDaR, a tumor-informed personalized MRD assay using dPCR-based SNV detection. It is a direct peer in oncology-focused MRD and offers additional clinical lab services overlap.

TypeBroad incumbent
Description

Foundation Medicine (a Roche subsidiary) is both the acquirer of SAGA and a broad incumbent in comprehensive genomic profiling; its broad CGP menu overlaps with Pathlight's tumor-informed testing approach as a platform partner.

TypeBroad incumbent
Description

Exact Sciences' Oncology segment (including Oncodetect MRD) competes in MRD and blood-based cancer detection. It is a broader diagnostic incumbent with a large commercial salesforce and established payor relationships.

7Tempus AI
TypeBroad incumbent
Description

Tempus operates in molecular residual disease and broad oncology profiling (xT, xR, xF). It overlaps with SAGA's clinical and biopharma use cases and benefits from a larger installed base and data footprint.

TypeEmerging player
Description

Caris offers MI Profile and is expanding into MRD and liquid biopsy. It overlaps with SAGA's biopharma partnering model and molecular profiling offerings, but with broader multi-omics positioning.

9Inivata (now part of NeoGenomics)
TypeEmerging player
Description

Inivata's RaDaR/InVision products target MRD with a personalized assay approach; folded into NeoGenomics, it remains relevant as a competing MRD technology stack with similar indications to Pathlight.

TypeRegional player
Description

Burning Rock is a China-based oncology liquid biopsy and MRD company. While geographically separate, it represents the international MRD/liquid-biopsy cohort and competes in the same indication landscape globally.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SAGA Diagnostics

Molecular Diagnosticssagadiagnostics.com

SAGA Diagnostics firmographics

Firmographics
Name
SAGA Diagnostics
Legal name
SAGA Diagnostics US, Inc.
Website
https://sagadiagnostics.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

SAGA Diagnostics industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Molecular residual disease testing
  • Liquid biopsy diagnostics
  • CtDNA cancer detection
  • Structural variant analysis
  • Cancer recurrence monitoring

Where SAGA Diagnostics is headquartered

Location

Headquarters

HQ city
Morrisville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

SAGA Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Clinical Laboratory Diagnostic Testing: SAGA operates a CLIA-certified laboratory offering the Pathlight MRD test to healthcare providers and patients in the U.S. Revenue is generated through Medicare reimbursement (for early-stage breast cancer) and commercial payor billing.
  2. Biopharma Testing Services: SAGA provides contract testing services to biopharma companies using Pathlight for clinical studies, biomarker discovery, trial enrollment support, and drug development programs. Services are tailored to each biopharma partner across early through late-stage cancer development programs.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goMedicare Reimbursement - Early-stage Breast Cancer

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

SAGA Diagnostics product offering

Product offering

Core offering

SAGA Diagnostics develops and commercializes Pathlight, an ultra-sensitive, blood-based molecular residual disease (MRD) test that combines whole genome sequencing with proprietary multiplex digital PCR to detect and track structural variants in circulating tumor DNA. The company operates a CLIA-certified laboratory in Morrisville, NC, providing diagnostic testing services to U.S. healthcare providers (initially for early-stage breast cancer recurrence monitoring) and biopharma companies for clinical trial support, biomarker discovery, and drug development programs.

Product overview

SAGA Diagnostics offers a unified product portfolio centered on the Pathlight MRD platform. Pathlight is a first-of-its-kind, tumor-informed multi-cancer molecular residual disease (MRD) test that combines whole genome sequencing with proprietary multiplex digital PCR to detect and track structural variants as biomarkers for ultra-sensitive cancer recurrence monitoring. The platform serves both commercial clinical testing (initially for early-stage breast cancer with expansion to colorectal cancer) and biopharma partnership services for clinical trial support and drug development programs.

Differentiator

Problem solved

Functional benefit

Brands

  • Pathlight: Ultra-sensitive, blood-based, multi-cancer molecular residual disease (MRD) test platform that uses whole genome sequencing and digital PCR to detect structural variants for cancer recurrence monitoring.

Products and services

  • Pathlight MRD Test Ultra-sensitive, blood-based, multi-cancer molecular residual disease (MRD) test that uses whole genome sequencing to identify tumor-specific structural variants and digital PCR to detect circulating tumor DNA at sub-part-per-million levels. Indicated for cancer recurrence monitoring and treatment response assessment, initially in early-stage breast cancer and expanded to colorectal cancer. Sold to oncologists, cancer centers, and academic medical centers.
  • Biopharma Testing Services Contract ctDNA-based liquid biopsy testing services for biopharma clinical development and translational research, including biomarker discovery, trial enrollment support, and longitudinal clinical trial monitoring using the Pathlight platform across solid tumors and hematologic malignancies. Sold to pharmaceutical and biotechnology companies of all sizes.

Quantifiable outcome

  • 100% sensitivity, 100% specificity, 13.7-month lead time to recurrence in stage I-III breast cancer
  • +3 more outcomes

Companies that use SAGA Diagnostics

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

SAGA Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature4 records

SAGA Diagnostics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Foundation Medicine (Roche subsidiary)flagshipStrategic or Co-development Partner · 16 April 2026Roche entered into definitive merger agreement to acquire SAGA Diagnostics for up to $595 million. Following closing (expected Q3 2026), Foundation Medicine will integrate SAGA's Pathlight platform into its diagnostic portfolio. Plans to leverage Roche's AXELIOS sequencing and Digital LightCycler PCR platforms for decentralized MRD solutions.
  • Top 10 Pharmaceutical Companies (unnamed)coreStrategic or Co-development PartnerPathlight is being used in clinical studies by multiple top 10 pharmaceutical companies for drug development, biomarker discovery, and clinical trial support. SAGA partners with biopharma companies of all sizes and development stages.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

SAGA Diagnostics competitors and assessment

Company assessment

Direct peers

  • Natera: Natera's Signatera is the leading tumor-informed MRD test using a personalized, multiplexed PCR (SNV-based) approach; it is the most directly comparable competitor in commercial-scale MRD testing for solid tumors.
  • Guardant Health: Guardant Health's Guardant Reveal is a tumor-informed MRD product using a hybrid methylation/ctDNA approach. Guardant is a direct peer in liquid biopsy and MRD, with deeper commercial payor coverage in oncology.
  • Personalis: Personalis offers NeXT Personal, a tumor-informed MRD test for solid tumors. It competes head-to-head with Pathlight in personalized ctDNA MRD detection, particularly in lung and breast cancer indications.
  • NeoGenomics: NeoGenomics sells RaDaR, a tumor-informed personalized MRD assay using dPCR-based SNV detection. It is a direct peer in oncology-focused MRD and offers additional clinical lab services overlap.

Broad incumbents

  • Foundation Medicine: Foundation Medicine (a Roche subsidiary) is both the acquirer of SAGA and a broad incumbent in comprehensive genomic profiling; its broad CGP menu overlaps with Pathlight's tumor-informed testing approach as a platform partner.
  • Exact Sciences: Exact Sciences' Oncology segment (including Oncodetect MRD) competes in MRD and blood-based cancer detection. It is a broader diagnostic incumbent with a large commercial salesforce and established payor relationships.
  • Tempus AI: Tempus operates in molecular residual disease and broad oncology profiling (xT, xR, xF). It overlaps with SAGA's clinical and biopharma use cases and benefits from a larger installed base and data footprint.

Emerging players

  • Caris Life Sciences: Caris offers MI Profile and is expanding into MRD and liquid biopsy. It overlaps with SAGA's biopharma partnering model and molecular profiling offerings, but with broader multi-omics positioning.
  • Inivata (now part of NeoGenomics): Inivata's RaDaR/InVision products target MRD with a personalized assay approach; folded into NeoGenomics, it remains relevant as a competing MRD technology stack with similar indications to Pathlight.

Regional players

  • Burning Rock Biotech: Burning Rock is a China-based oncology liquid biopsy and MRD company. While geographically separate, it represents the international MRD/liquid-biopsy cohort and competes in the same indication landscape globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

SAGA Diagnostics social profiles

Digital presence

SAGA Diagnostics compliance and trust

Trust signal

Compliance4 records

SAGA Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SAGA Diagnostics leadership team

Management profile

Number of profiles

Profiles4 records

SAGA Diagnostics subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

SAGA Diagnostics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SAGA Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SAGA Diagnostics

What does SAGA Diagnostics do?

SAGA Diagnostics develops and commercializes Pathlight, an ultra-sensitive, blood-based molecular residual disease (MRD) test that combines whole genome sequencing with proprietary multiplex digital PCR to detect and track structural variants in circulating tumor DNA. The company operates a CLIA-certified laboratory in Morrisville, NC, providing diagnostic testing services to U.S. healthcare providers (initially for early-stage breast cancer recurrence monitoring) and biopharma companies for clinical trial support, biomarker discovery, and drug development programs.

Is SAGA Diagnostics a public or private company?

SAGA Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was SAGA Diagnostics founded?

SAGA Diagnostics was founded in 2016. It employs 51 to 100 people.

Where is SAGA Diagnostics based?

SAGA Diagnostics is headquartered in Morrisville, United States, in the North America region.

How does SAGA Diagnostics make money?

Two revenue lines are on record. Clinical Laboratory Diagnostic Testing is the primary driver. The others are biopharma Testing Services.

Who are SAGA Diagnostics's main competitors?

Direct peers on record are Natera, Guardant Health, Personalis and NeoGenomics. Broad incumbents are Foundation Medicine, Exact Sciences and Tempus AI. Emerging players are Caris Life Sciences and Inivata (now part of NeoGenomics). Burning Rock Biotech is listed as a regional player.

Does SAGA Diagnostics have an API?

No public API is recorded for SAGA Diagnostics.

What industry is SAGA Diagnostics in?

SAGA Diagnostics's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device NetworkCountable Labs raises $26m for PCR technology advancementCountable Labs raised $26m led by ARCH Venture Partners to advance its single-molecule PCR technology, which it claims is at least 10 times more sensitive than conventional PCR. The funding supports commercialization and follows a European CE mark in March 2026. The company also appointed Christopher Citraro as vice president of global sales.The Motley FoolPresident Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks?Trump's MFN policy could hurt drugmakers' profits, but Johnson & Johnson and Roche are recommended as resilient investments. JNJ expects $100.8B revenue this year, while Roche's diagnostics and pipeline, including a $595M SAGA Diagnostics acquisition, offer diversification.BioSpaceSAGA Diagnostics to Present Data on Ultrasensitive Pathlight™ MRD Test in Breast, Colon, and Rectal Cancers at ASCO 2026SAGA Diagnostics will present three abstracts on its Pathlight MRD test at ASCO 2026 in Chicago, covering breast, colon, and rectal cancers. The data includes retrospective ctDNA kinetics in metastatic breast cancer and real-world outcomes in localized colorectal cancer. The company highlights the test's ultrasensitive structural variant-based approach for treatment monitoring and recurrence assessment.PharmaVoiceIs pharma missing the boat on diagnostics?The article examines the limited engagement of pharmaceutical companies in the diagnostics sector despite the growing importance of testing tools for precision medicine, noting that global venture funding for diagnostics totaled just $1.7 billion last year compared to $15.5 billion for AI and machine learning. Major pharma moves highlighted include Roche's $595 million acquisition of SAGA Diagnostics, Abbott's $21 billion purchase of Exact Sciences, and continued investment by Johnson & Johnson in diagnostics through partnerships and device development. The piece also profiles Cleveland Diagnostics, which received its first FDA approval in December for a prostate cancer detection test and raised funding from Novo Holdings, while exploring how AI could eventually integrate pharma and diagnostics data to improve patient care pathways.GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the SwiRoche reported Q1 2026 group sales of CHF 14.7 billion, representing +6% growth at constant exchange rates but -5% when reported in Swiss francs due to significant franc appreciation against most currencies. The Pharmaceuticals Division led growth at +7% CER, driven by strong demand for Xolair, Phesgo, Hemlibra, Vabysmo and Ocrevus, which collectively achieved CHF 5.3 billion in sales (+14% CER), while the Diagnostics Division grew +3% CER. The company also announced positive phase III trial data for multiple pipeline compounds, entered a definitive agreement to acquire SAGA Diagnostics, and confirmed its 2026 full-year outlook for mid-single-digit sales growth.MarketScreenerThe Price of PatienceRoche reported Q1 revenue of CHF 14.72bn, down 5% year-over-year, while its stock rebounded 28% in 2025. The Basel-based group is shifting focus to obesity and metabolic diseases, trading at 17x expected 2026 earnings with a dividend yield above 3%. Its next update is May 12, 2026.Clinical Lab ProductsFoundation Medicine to Acquire SAGA Diagnostics' Cancer Monitoring TechnologyFoundation Medicine, a precision medicine company affiliated with Roche, has agreed to acquire SAGA Diagnostics' molecular residual disease platform Pathlight as part of Roche's broader $595 million acquisition of SAGA. The Pathlight platform uses whole genome sequencing and digital PCR technology to detect cancer recurrence with ultra-sensitivity, currently available in the US and covered by Medicare for early-stage breast cancer. The transaction is expected to close by Q3 2026, after which the technology will be fully integrated into Foundation Medicine's portfolio to support treatment selection and disease monitoring.ArcticstartupSweden’s SAGA Diagnostics set for acquisition as Roche builds out MRD infrastructureRoche has agreed to acquire Swedish molecular diagnostics company SAGA Diagnostics for up to $595 million, with the deal expected to close by Q3 2026. SAGA's Pathlight MRD platform, which uses whole genome sequencing and digital PCR to detect cancer recurrence through structural variant tracking, will be integrated into Roche's Foundation Medicine subsidiary. The acquisition positions SAGA's technology as a core component of Roche's precision oncology portfolio, enabling expansion of the platform from its current U.S. availability in early-stage breast cancer into additional cancer types and international markets.FierceBiotechRoche boosts diagnostics offerings with $595M Saga buyoutRoche has agreed to acquire Saga Diagnostics for $595 million, strengthening its Foundation Medicine subsidiary's diagnostic testing portfolio with the company's personalized tumor-informed molecular residual disease (MRD) platform called Pathlight. The platform, already commercialized for early breast and colorectal cancer detection, uses structural variant biology to achieve ultra-sensitivity in cancer detection, with Saga previously guiding to approximately $150 million in 2028 sales. The deal will enable Foundation Medicine to leverage Roche's existing sequencing and PCR platforms to develop a decentralized MRD solution for broader patient access worldwide.Medical Device NetworkRoche builds MRD testing arsenal in $595m Saga Diagnostics buyoutRoche has agreed to acquire MRD testing specialist Saga Diagnostics and its Pathlight platform for $595 million through its precision medicine subsidiary Foundation Medicine. The Pathlight platform combines digital PCR with whole genome sequencing to detect molecular residual disease and assess cancer recurrence. The acquisition will complement Roche's existing MRD diagnostic tools as the company positions itself in what is described as one of the fastest-growing areas within diagnostics, amid a broader shift toward precision medicine in cancer care.